Evidence map›Paper›PMID 42387184›Full record

ReviewActa pharmacologica Sinica2026

Molecular mechanisms for sustaining cancer stem cells characteristics and targeted therapeutic strategies.

Chen-Xi Zhao, Shu-Yun Wang, Ke Li

Abstract readReview
PubMed Publisher
In one paragraph

Review in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Chen-Xi Zhao *Shanghai Key Laboratory of Anesthesiology and Brain Functional Modulation, Clinical Research Center for Anesthesiology and Perioperative Medicine, Translational Research Institute of Brain and Brain-Like Intelligence, Department of Anesthesiology and Perioperative Medicine, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, 200434, China.
Shu-Yun Wang *State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Ke LiState Key Laboratory of Bioactive Substances and Functions of Natural Medicines, NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China. like1986@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem cells (CSCs) are a subpopulation of tumor cells with stem cell-like properties, which are endowed with unique self-renewal capacity and heterogeneity. Specifically, they drive tumor initiation, progression, recurrence, and therapeutic resistance. As the core drivers of tumor development and treatment resistance, CSCs exhibit distinct metabolic characteristics that sustain their self-renewal and differentiation potential. Various cells in the tumor microenvironment (TME) interact with CSCs, thereby creating a favorable niche for maintaining CSCs stemness. Furthermore, the metabolic patterns of CSCs themselves can modulate the functions of other TME-resident cells; collectively, these bidirectional interactions promote tumor recurrence and therapeutic resistance. A growing body of evidence has confirmed the critical role of CSCs in tumor progression, drug resistance, and recurrence, which lays a solid foundation for the development of potential therapeutic targets and intervention strategies. This review systematically summarizes the biological characteristics and targeted therapeutic strategies of CSCs, and explores potential directions to break through current therapeutic bottlenecks in combination with the latest status of clinical research.

Indexed as

cancer stem cellscharacteristicsdifferentiationself-renewal capacitytargeted therapy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.